Melanie Weigert
YOU?
Author Swipe
View article: Supplementary Table 4 from A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer
Supplementary Table 4 from A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer Open
LC-MS based proteomics data of all 144 samples
View article: Supplementary Table 5 from A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer
Supplementary Table 5 from A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer Open
Significantly up – and downregulated proteins in the tumor and stroma of synchronous cancers
View article: Supplementary Figures and Legends 1 from A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer
Supplementary Figures and Legends 1 from A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer Open
Supplementary Figures and Legends
View article: Supplementary Table 1 from A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer
Supplementary Table 1 from A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer Open
Clinico-pathologic patient characteristics
View article: Supplementary Table 6 from A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer
Supplementary Table 6 from A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer Open
Top 20 discriminating proteins between dual and single cancers
View article: Supplementary Table 3 from A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer
Supplementary Table 3 from A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer Open
Overlap of patients and shared mutations between Anglesio and colleagues and this study
View article: Data from A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer
Data from A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer Open
Purpose:Increasing genomics-based evidence suggests that synchronous endometrial and ovarian cancer (SEOC) represents clonally related primary and metastatic tumors. A systematic analysis of the global protein landscape of SEOCs, heretofor…
View article: Supplementary Table 2 from A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer
Supplementary Table 2 from A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer Open
Top 30 mutated genes in single (ovary, endometrium) and dual (SEOC) cancers
View article: A cell atlas of the human fallopian tube throughout the menstrual cycle and menopause
A cell atlas of the human fallopian tube throughout the menstrual cycle and menopause Open
View article: Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10
Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10 Open
Disseminated cancer cells in the peritoneal fluid often colonize omental fat-associated lymphoid clusters but the mechanisms are unclear. Here, we identify that innate-like B cells accumulate in the omentum of mice and women with early-sta…
View article: LABS: linear amplification-based bisulfite sequencing for ultrasensitive cancer detection from cell-free DNA
LABS: linear amplification-based bisulfite sequencing for ultrasensitive cancer detection from cell-free DNA Open
View article: 5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer
5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer Open
View article: A Cellular atlas of the human fallopian tube reveals the metamorphosis of secretory epithelial cells during the menstrual cycle and menopause
A Cellular atlas of the human fallopian tube reveals the metamorphosis of secretory epithelial cells during the menstrual cycle and menopause Open
The fallopian tube, connecting the uterus with the ovary, is a dynamic organ that undergoes cyclical changes and is the site of several diseases, including serous cancer. Here, we use single-cell technologies to construct a comprehensive c…
View article: Diagnostic Performance of Ultrasonography-Based Risk Models in Differentiating Between Benign and Malignant Ovarian Tumors in a US Cohort
Diagnostic Performance of Ultrasonography-Based Risk Models in Differentiating Between Benign and Malignant Ovarian Tumors in a US Cohort Open
Importance Ultrasonography-based risk models can help nonexpert clinicians evaluate adnexal lesions and reduce surgical interventions for benign tumors. Yet, these models have limited uptake in the US, and studies comparing their diagnosti…
View article: Supplementary Figure 3 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Supplementary Figure 3 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer Open
SPHK1 promotes proliferation, migration and clonogenicity in a representative HGSOC cell line.
View article: Supplementary Figure 6 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Supplementary Figure 6 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer Open
Silencing SPHK1 promotes resistance to metformin-induced cytotoxicity.
View article: Supplementary Figure 1 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Supplementary Figure 1 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer Open
Analysis of S1P-related enzymes in two OvCa cell lines.
View article: Supplementary Figure 4 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Supplementary Figure 4 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer Open
Metformin inhibits induction of SPHK1 transcription by HIFs.
View article: Supplementary Figure 2 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Supplementary Figure 2 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer Open
Analysis of SPHK1 expression in multiple OvCa cell lines.
View article: Supplementary Figure 7 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Supplementary Figure 7 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer Open
SPHK1 expression does not alter other markers of metformin sensitivity.
View article: Supplementary Figure 5 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Supplementary Figure 5 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer Open
Metformin prevents nuclear localization of HIF1α in Kuramochi cells.
View article: Supplementary Figure 1 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Supplementary Figure 1 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer Open
Analysis of S1P-related enzymes in two OvCa cell lines.
View article: Supplementary Figure 3 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Supplementary Figure 3 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer Open
SPHK1 promotes proliferation, migration and clonogenicity in a representative HGSOC cell line.
View article: Supplementary Figure 5 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Supplementary Figure 5 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer Open
Metformin prevents nuclear localization of HIF1α in Kuramochi cells.
View article: Supplementary Figure 8 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Supplementary Figure 8 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer Open
Knockdown of SPHK1 in OvCa cells.
View article: Supplementary Figure 2 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Supplementary Figure 2 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer Open
Analysis of SPHK1 expression in multiple OvCa cell lines.
View article: Supplementary Figure 6 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Supplementary Figure 6 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer Open
Silencing SPHK1 promotes resistance to metformin-induced cytotoxicity.
View article: Data from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Data from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer Open
The role of phospholipid signaling in ovarian cancer is poorly understood. Sphingosine-1-phosphate (S1P) is a bioactive metabolite of sphingosine that has been associated with tumor progression through enhanced cell proliferation and motil…
View article: Supplementary Figure 7 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Supplementary Figure 7 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer Open
SPHK1 expression does not alter other markers of metformin sensitivity.
View article: Supplementary Figure 4 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Supplementary Figure 4 from SPHK1 Is a Novel Target of Metformin in Ovarian Cancer Open
Metformin inhibits induction of SPHK1 transcription by HIFs.